[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Hidradenitis Suppurativa R&D Pipeline Analysis Report, H2-2018

August 2018 | 80 pages | ID: HA6C0858442EN
VPAResearch

US$ 1,980.00 US$ 2,200.00 -10 %
Offer valid until December 31, 2024!

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Hidradenitis Suppurativa Drug Development Pipeline Study is the latest publication from VPA Research with comprehensive information of Hidradenitis Suppurativa pipeline products.

The Hidradenitis Suppurativa pipeline guide presents complete overview of drugs currently being developed for Hidradenitis Suppurativa. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Hidradenitis Suppurativa pipeline candidate.

Research and Development progress along with latest news related to each of the Hidradenitis Suppurativa pipeline candidates is included.
  • Major companies participating in therapeutic development of Hidradenitis Suppurativa are included in this pipeline report. Company wise pre clinical and clinical products along with details of drug originator, co developers/ licensors are provided.
  • Amid strong interest for cure of Hidradenitis Suppurativa from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Hidradenitis Suppurativa clinical and pre clinical products.
  • The report assists in identifying potential upcoming companies and drugs in Hidradenitis Suppurativa pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
  • Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.
SCOPE OF HIDRADENITIS SUPPURATIVA PIPELINE REPORT INCLUDES
  • Panorama of Hidradenitis Suppurativa pipeline markets including statistics on therapeutic drugs and companies involved
  • Hidradenitis Suppurativa Pipeline candidates across various development phases including both pre clinical, discovery and clinical stages are covered
  • Hidradenitis Suppurativa pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
  • Overview of companies participating in Hidradenitis Suppurativa pipeline with short introduction to their businesses and pipeline projects
  • For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co developer and licensee are provided.
  • Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Hidradenitis Suppurativa pipeline therapeutics
REASONS TO BUY
  • Get clear understanding of the entire Hidradenitis Suppurativa pipeline, with details on active projects
  • Get in detail information of each product with updated information on each project along with key milestones
  • Know the list of companies participating in global Hidradenitis Suppurativa pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
Please Note: The report will be delivered in 2 working days after purchase
I. KEY FINDINGS

1. Companies Investing in Hidradenitis Suppurativa Pipeline include
  Number of Companies with Hidradenitis Suppurativa projects in pre clinical Development
  Number of Companies with Hidradenitis Suppurativa projects in Clinical Development
  Hidradenitis Suppurativa Pipeline Companies based in Americas
  Hidradenitis Suppurativa Pipeline Companies based in Europe
  Hidradenitis Suppurativa Pipeline Companies based in Asia Pacific
  Hidradenitis Suppurativa Pipeline Companies based in Rest of the World
2. Pipeline Candidates include
  Hidradenitis Suppurativa Pipeline Agents in pre clinical/Discovery stage of Development
  Hidradenitis Suppurativa Pipeline Agents in Clinical Development stage
  Hidradenitis Suppurativa Pipeline Therapeutic Compounds received special status
  Mechanism of Action of most pipeline Drugs
  Small molecules among the Hidradenitis Suppurativa Pipeline agents

II. INSIGHTS INTO HIDRADENITIS SUPPURATIVA PIPELINE

1. Disease Overview
  Introduction to Hidradenitis Suppurativa
  Symptoms and Causes of Hidradenitis Suppurativa
  Treatment or Prevention Options for Hidradenitis Suppurativa
  Other Details
2. Phase wise Pipeline Compounds
  Hidradenitis Suppurativa Pipeline Pre Clinical/Discovery stage Drugs
  Hidradenitis Suppurativa Pipeline Phase 1 stage Drugs
  Hidradenitis Suppurativa Pipeline Phase 2 stage Drugs
  Hidradenitis Suppurativa Pipeline Phase 3 stage Drugs
  Hidradenitis Suppurativa Pipeline Pre Registration stage Drugs
3. Company wise Hidradenitis Suppurativa Pipeline Compounds
4. Hidradenitis Suppurativa Pipeline by Mechanism of Action

III. HIDRADENITIS SUPPURATIVA PIPELINE COMPOUND DETAILS

Drug Details
1. Snapshot
  Name of the Therapeutic Agent
  Originator
  Developing Company
  Co Developer/License Partner
  Orphan Drug/Fast Track/Designation
  Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. HIDRADENITIS SUPPURATIVA PIPELINE COMPANY BRIEFS

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL HIDRADENITIS SUPPURATIVA PIPELINE MARKET

VI. APPENDIX

1. About Us
2. Research Methodology
3. Contact Information

The report will be delivered within 2 working days after procurement. Some of the sections depicted above may be modified in accordance with relevancy and availability


More Publications